Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294502105> ?p ?o ?g. }
- W2294502105 abstract "ABSTRACT Aim: Combined chemotherapy requires compromises in terms of dosage and treatment interval due to toxicities. The sequential administration of monotherapies allows high doses of single substances and dose-dense intervals. So far, such regimens have proved to be very effective in early breast cancer with high risk of recurrence. Nab-paclitaxel (nP) leads to a more favorable toxicity profile and greater efficacy compared with solvent-based taxanes. Methods: The GAIN2 study compares toxicity and efficacy of a pre-defined dose-dense high-dose regimen (EnPC) with a dose-dense regimen, where single doses are adjusted depending on individual haematological and non-haematological toxicities (dtEC-dtD). Primary endpoint is the invasive disease-free survival in patients with primary node-positive or high-risk node-negative breast cancer. Two safety interim analyses after 200 and 900 patients who have completed chemotherapy are planned. The results of the first safety analysis will be presented. In addition to the standard analyses for haematological and non-haematological toxicities, any affections of the cranial nerves as well as the rate of macular degeneration and anaphylactic reactions are of special interest. Results: In terms of hematological adverse events, the rate of febrile neutropenia grade 3-4 (14% vs. 5%) and thrombocytopenia grade 3-4 (14% vs. 5%) was significantly increased in the EnPC arm. As for the non-haematological side effects, there were significantly more patients developing anorexia (grade 1-4) in the EnPC arm. There were no differences between the treatment arms for the toxicities of special interest. In the EnPC arm, 28% required dose-reductions due to hematological toxicities compared with only 11% in the dtEC dtD arm (p = 0.002). The dose could be escalated to the maximum in half of the patients receiving dtEC dtD. In 7% of women a reduction was required in the 4th cycle of docetaxel. Conclusions: Due to similar toxicity profiles, the study will be continued without changes. Disclosure: A. Schneeweiss: Honoraria, Research Funding and Advisory Role: Celgene and Roche; G. von Minckwitz: Honoraria and Research Funding: Amgen, Celgene and Roche; V. Mobus: Honoraria and Research Funding: Amgen, GSK, Sanofi-Aventis, Pfizer, Roche. All other authors have declared no conflicts of interest." @default.
- W2294502105 created "2016-06-24" @default.
- W2294502105 creator A5003202173 @default.
- W2294502105 creator A5011410319 @default.
- W2294502105 creator A5013148496 @default.
- W2294502105 creator A5020427785 @default.
- W2294502105 creator A5024142887 @default.
- W2294502105 creator A5035772972 @default.
- W2294502105 creator A5036531617 @default.
- W2294502105 creator A5052778557 @default.
- W2294502105 creator A5054463319 @default.
- W2294502105 creator A5062611898 @default.
- W2294502105 creator A5064127351 @default.
- W2294502105 creator A5068818204 @default.
- W2294502105 creator A5075265190 @default.
- W2294502105 creator A5081829270 @default.
- W2294502105 creator A5087559224 @default.
- W2294502105 creator A5089392438 @default.
- W2294502105 date "2014-09-01" @default.
- W2294502105 modified "2023-10-17" @default.
- W2294502105 title "Gain2: Adjuvant Phase III Trial Comparing an Intensified Dose-Dense Adjuvant Therapy with Enpc Compared with a Dose-Dense, Dose-Adapted Therapy with Dtec Dtdocetaxel in Patients with Primary Breast Cancer and a High Risk of Recurrence" @default.
- W2294502105 doi "https://doi.org/10.1093/annonc/mdu327.12" @default.
- W2294502105 hasPublicationYear "2014" @default.
- W2294502105 type Work @default.
- W2294502105 sameAs 2294502105 @default.
- W2294502105 citedByCount "0" @default.
- W2294502105 crossrefType "journal-article" @default.
- W2294502105 hasAuthorship W2294502105A5003202173 @default.
- W2294502105 hasAuthorship W2294502105A5011410319 @default.
- W2294502105 hasAuthorship W2294502105A5013148496 @default.
- W2294502105 hasAuthorship W2294502105A5020427785 @default.
- W2294502105 hasAuthorship W2294502105A5024142887 @default.
- W2294502105 hasAuthorship W2294502105A5035772972 @default.
- W2294502105 hasAuthorship W2294502105A5036531617 @default.
- W2294502105 hasAuthorship W2294502105A5052778557 @default.
- W2294502105 hasAuthorship W2294502105A5054463319 @default.
- W2294502105 hasAuthorship W2294502105A5062611898 @default.
- W2294502105 hasAuthorship W2294502105A5064127351 @default.
- W2294502105 hasAuthorship W2294502105A5068818204 @default.
- W2294502105 hasAuthorship W2294502105A5075265190 @default.
- W2294502105 hasAuthorship W2294502105A5081829270 @default.
- W2294502105 hasAuthorship W2294502105A5087559224 @default.
- W2294502105 hasAuthorship W2294502105A5089392438 @default.
- W2294502105 hasBestOaLocation W22945021051 @default.
- W2294502105 hasConcept C121608353 @default.
- W2294502105 hasConcept C126322002 @default.
- W2294502105 hasConcept C141071460 @default.
- W2294502105 hasConcept C143998085 @default.
- W2294502105 hasConcept C197934379 @default.
- W2294502105 hasConcept C203092338 @default.
- W2294502105 hasConcept C2776694085 @default.
- W2294502105 hasConcept C2777063308 @default.
- W2294502105 hasConcept C2777863537 @default.
- W2294502105 hasConcept C2777982462 @default.
- W2294502105 hasConcept C2778850193 @default.
- W2294502105 hasConcept C2781413609 @default.
- W2294502105 hasConcept C29730261 @default.
- W2294502105 hasConcept C530470458 @default.
- W2294502105 hasConcept C535046627 @default.
- W2294502105 hasConcept C61943457 @default.
- W2294502105 hasConcept C71924100 @default.
- W2294502105 hasConceptScore W2294502105C121608353 @default.
- W2294502105 hasConceptScore W2294502105C126322002 @default.
- W2294502105 hasConceptScore W2294502105C141071460 @default.
- W2294502105 hasConceptScore W2294502105C143998085 @default.
- W2294502105 hasConceptScore W2294502105C197934379 @default.
- W2294502105 hasConceptScore W2294502105C203092338 @default.
- W2294502105 hasConceptScore W2294502105C2776694085 @default.
- W2294502105 hasConceptScore W2294502105C2777063308 @default.
- W2294502105 hasConceptScore W2294502105C2777863537 @default.
- W2294502105 hasConceptScore W2294502105C2777982462 @default.
- W2294502105 hasConceptScore W2294502105C2778850193 @default.
- W2294502105 hasConceptScore W2294502105C2781413609 @default.
- W2294502105 hasConceptScore W2294502105C29730261 @default.
- W2294502105 hasConceptScore W2294502105C530470458 @default.
- W2294502105 hasConceptScore W2294502105C535046627 @default.
- W2294502105 hasConceptScore W2294502105C61943457 @default.
- W2294502105 hasConceptScore W2294502105C71924100 @default.
- W2294502105 hasLocation W22945021051 @default.
- W2294502105 hasOpenAccess W2294502105 @default.
- W2294502105 hasPrimaryLocation W22945021051 @default.
- W2294502105 hasRelatedWork W1872181102 @default.
- W2294502105 hasRelatedWork W1976439078 @default.
- W2294502105 hasRelatedWork W1980041456 @default.
- W2294502105 hasRelatedWork W2002506311 @default.
- W2294502105 hasRelatedWork W2011699001 @default.
- W2294502105 hasRelatedWork W2046256468 @default.
- W2294502105 hasRelatedWork W2112950837 @default.
- W2294502105 hasRelatedWork W2157516981 @default.
- W2294502105 hasRelatedWork W2164520290 @default.
- W2294502105 hasRelatedWork W2275598600 @default.
- W2294502105 hasRelatedWork W2289353494 @default.
- W2294502105 hasRelatedWork W2313437566 @default.
- W2294502105 hasRelatedWork W2612724718 @default.
- W2294502105 hasRelatedWork W2768511567 @default.
- W2294502105 hasRelatedWork W2792955995 @default.
- W2294502105 hasRelatedWork W2889673459 @default.
- W2294502105 hasRelatedWork W3008773521 @default.
- W2294502105 hasRelatedWork W3016989092 @default.
- W2294502105 hasRelatedWork W3130810088 @default.